- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | VISEN PHARMA-B (02561): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 3 | HKEx | ||
| 27.08. | VISEN PHARMA-B (02561): (1) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MOTNHS ENDED JUNE 30, 2025; (2) RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT ... | - | HKEx | ||
| VISEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.08. | VISEN PHARMA-B (02561): DATE OF BOARD MEETING | - | HKEx | ||
| 27.06. | VISEN PHARMA-B (02561): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 27.06. | VISEN PHARMA-B (02561): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 27 JUNE 2025; (2) RETIREMENT OF NON-EXECUTIVE DIRECTORS; (3) CHANGE OF ... | - | HKEx | ||
| 12.06. | VISEN PHARMA-B (02561): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 12.06. | VISEN PHARMA-B (02561): SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025 AT 3:00 P.M. | 1 | HKEx | ||
| 12.06. | VISEN PHARMA-B (02561): (1) CONTINUING CONNECTED TRANSACTION IN RELATION TO THE COMMERCIAL SUPPLY FRAMEWORK AGREEMENT; (2) PROPOSED GRANT OF AWARD SHARES; ... | - | HKEx | ||
| 12.06. | VISEN PHARMA-B (02561): GRANT OF AWARD SHARES | 3 | HKEx | ||
| 12.06. | VISEN PHARMA-B (02561): CONTINUING CONNECTED TRANSACTION COMMERCIAL SUPPLY FRAMEWORK AGREEMENT | - | HKEx | ||
| 30.04. | VISEN PHARMA-B (02561): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 30.04. | VISEN PHARMA-B (02561): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025 AT 3:00 P.M. | - | HKEx | ||
| 30.04. | VISEN PHARMA-B (02561): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES ... | - | HKEx | ||
| 30.04. | VISEN PHARMA-B (02561): 2024 ANNUAL REPORT | - | HKEx | ||
| 25.04. | VISEN PHARMA-B (02561): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 25.04. | VISEN PHARMA-B (02561): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 17.04. | VISEN PHARMA-B (02561): STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION | 3 | HKEx | ||
| 27.03. | VISEN PHARMA-B (02561): FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
| 24.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 24.03.2025 | 574 | Xetra Newsboard | The following instruments on XETRA do have their first trading 24.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.03.2025
Aktien
1 KYG93Y5D1039 VISEN Pharmaceuticals
2... ► Artikel lesen | |
| 20.03. | VISEN PHARMA-B (02561): ANNOUNCEMENT OF ALLOTMENT RESULTS | 2 | HKEx |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| APOGEE THERAPEUTICS | 36,860 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,210 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| BEAM THERAPEUTICS | 21,280 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 16,930 | 0,00 % | Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung | ||
| AVIDITY BIOSCIENCES | 40,190 | 0,00 % | Avidity Biosciences schließt Kapitalerhöhung über 690 Millionen US-Dollar ab | ||
| CG ONCOLOGY | 34,600 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
| RAPPORT THERAPEUTICS | 24,730 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | ||
| TOURMALINE BIO | 47,650 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 6,930 | 0,00 % | Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa | DJ Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa
Von Adriano Marchese
DOW JONES--Novartis hat eine potenziell milliardenschwere Entwicklungspartnerschaft mit dem US-Biotechunternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,850 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,065 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,410 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report |
VISEN PHARMACEUTICALS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,100 (+2,11 %) liegt der Kurs bei 4,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VISEN PHARMACEUTICALS finden Sie auf Wallstreet Online.